

POLY MEDICURE LIMITED							
Regd. Office: First Floor, 12, Sant Nagar, East of Kailash, New Delhi - 110 065							
STATEMENT OF STANDALONE / CONSOLIDATED AUDITED RESULTS FOR THE QUARTER AND FOR THE YEAR ENDED 31/03/2012							
(₹ In Lacs)							
Particulars	Standalone			Year ended		Consolidated	
	Quarter ended		31.03.2011 (Unaudited)	Year ended		Year ended	
	31.03.2012 (Unaudited)	31.12.2011 (Unaudited)		31.03.2012 (Audited)	31.03.2011 (Audited)	31.03.2012 (Audited)	31.03.2011 (Audited)
1 Income from operations							
a) Net sales / income from operations	3,485.00	3,389.53	4,435.72	20,247.75	16,451.97	21,058.58	16,780.35
b) (Net of excise duty)							
c) Other operating income	174.46	128.51	185.42	544.11	514.78	644.11	514.78
Total income from operations (net)	3,714.59	3,518.04	4,621.14	20,891.86	16,966.75	21,702.79	17,295.13
2 Expenses							
a) Cost of materials consumed	1,425.11	1,856.56	1,571.97	8,501.47	6,015.24	6,985.14	6,168.98
b) Purchases of stock-in-trade	1,06.89	170.73	102.58	589.60	174.77	689.60	174.77
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	111.76	(56.49)	67.00	(115.02)	98.61	(115.02)	98.61
d) Employee benefits expense	755.30	693.73	658.86	3,293.35	2,665.71	3,438.11	2,746.73
e) Depreciation and amortisation expenses	266.47	235.99	232.13	995.52	858.79	1,174.01	942.32
f) Other expenses	1,979.82	1,552.37	1,132.40	5,906.92	4,385.53	6,013.60	4,440.80
Total expenses	4,761.54	4,672.89	3,764.94	17,372.05	14,198.65	18,185.44	14,572.21
3 Profit from operations before other income, finance costs and exceptional items (1-2)	953.05	845.15	856.20	3,519.81	2,768.10	3,517.35	2,722.92
4) Other income	74.95	11.50	17.69	51.95	39.31	61.95	39.31
5 Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)	988.01	856.65	873.89	3,581.76	2,807.41	3,579.30	2,762.23
6) Finance costs	187.51	229.25	98.43	593.36	414.53	695.47	421.22
7 Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 + 6)	790.50	627.40	775.46	2,888.40	2,392.88	2,883.83	2,341.01
8) Exceptional items							
9) Profit / (Loss) from ordinary activities before tax (7 + 8)	790.50	627.40	775.46	2,888.40	2,392.88	2,883.83	2,341.01
10) Tax expense	203.47	226.45	63.11	957.44	773.86	962.69	224.04
11 Net Profit / (Loss) from ordinary activities after tax (9 + 10)	587.03	400.95	712.35	1,925.96	2,169.02	1,921.14	2,116.97
12) Extraordinary items							
13 Net Profit / (Loss) for the period (11 + 12)	587.03	400.95	712.35	1,925.96	2,169.02	1,921.14	2,116.97
14) Share of profit / (loss) of associates						19.43	44.52
15) Loss attributable to Minority interest						6.36	5.66
16 Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 + 14 + 15)	587.03	400.95	712.35	1,925.96	2,169.02	1,946.93	2,167.15
17) Paid up equity share capital (face value of ₹ 10 each)	1,101.25	1,101.25	1,101.25	1,101.25	1,101.25	1,101.25	1,101.25
18) Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year				8,168.33	6,676.50	8,248.87	6,705.23
19) Earnings per share (before extraordinary items) (not annualised). (Basic and Diluted)	4.56	3.64	6.47	17.49	19.70	17.62	19.63
A PARTICULARS OF SHAREHOLDING							
1) Public Shareholding							
Number of shares	56,49,781	56,49,781	56,49,781	56,49,781	56,49,781	56,49,781	56,49,781
Percentage of shareholding	51.30%	51.30%	51.30%	51.30%	51.30%	51.30%	51.30%
2) Promoters and Promoter Group Shareholding							
a) Pledged / Encumbered							
Number of shares							
Percentage of shares (as a % of the total shareholding of promoter and promoter group)							
Percentage of shares (as a % of the total share capital of the company)							
b) Non-encumbered							
Number of shares	5362719	5362719	5362719	5362719	5362719	5362719	5362719
Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%	100%	100%
Percentage of shares (as a % of the total share capital of the company)	48.70%	48.70%	48.70%	48.70%	48.70%	48.70%	48.70%

Standalone / Consolidated Statement of Assets and Liabilities				
Particulars	Standalone		Consolidated	
	As at	As at	As at	As at
	31/03/2012	31/03/2011	31/03/2012	31/03/2011
A EQUITY AND LIABILITIES				
1 Shareholders' funds				
(a) Share Capital	1,101.25	1,101.25	1,101.25	1,101.25
(b) Reserves and surplus	8,188.33	6,676.50	8,248.86	6,705.22
Sub-total - Shareholders' funds	9,289.58	7,777.75	9,350.13	7,806.47
2 Minority interest			6.28	10.97
3 Non-current liabilities				
(a) Long term borrowings	1,831.24	1,244.17	1,831.24	1,244.17
(b) Deferred tax liab. (net)	536.94	316.93	536.94	316.92
(c) Other long term liabilities	38.02	133.54	28.02	133.54
(d) Long term provisions	126.00	115.61	126.00	115.61
Sub-total - Non-current liabilities	2,734.20	1,810.25	2,734.20	1,810.24
4 Current liabilities				
(a) Short-term borrowings	1,585.32	1,633.64	1,585.32	1,633.64
(b) Trade payables	1,897.51	1,527.85	1,991.25	1,810.01
(c) Other current liabilities	2,026.68	2,006.55	2,064.43	2,023.34
(d) Short term provisions	453.10	438.53	443.10	439.53
Sub-total - Current liabilities	5,952.71	5,607.57	6,084.12	5,706.51
TOTAL - EQUITY AND LIABILITIES	17,976.49	15,195.57	18,174.61	15,334.19
B ASSETS				
1 Non-current assets				
(a) Fixed assets	6,673.33	7,250.83	9,004.44	7,741.96
(b) Goodwill on consolidation	-	-	30.57	30.57
(c) Non-current investments	591.29	691.39	239.96	202.50
(d) Long-term loans and advances	940.99	896.65	723.17	802.55
(e) Other non-current assets	90.52	71.55	90.62	71.55
Sub-total - Non-current assets	10,296.33	8,912.42	10,088.56	8,849.23
2 Current assets				
(a) Inventories	2,791.66	2,412.19	3,004.92	2,526.64
(b) Trade receivables	3,230.42	2,622.94	3,445.82	2,874.59
(c) Cash and cash equivalents	52.90	50.83	58.17	60.99
(d) Short term loans and advances	926.22	790.25	680.95	815.84
(e) Other current assets	678.96	406.90	681.11	406.90
Sub-total - Current assets	7,680.16	6,283.15	8,086.05	6,484.96
TOTAL - ASSETS	17,976.49	15,195.57	18,174.61	15,334.19

Notes:

1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 28th May, 2012.

2. The figures of last quarter for the current year and for the previous year are the balancing figures between the audited figures in respect of the full financial year ended 31st March and the unaudited published year-to-date figures upto the third quarter ended 31st December.


3. The Board of Directors have recommended a dividend of ₹ 3 per equity share of ₹ 10 each, subject to approval of shareholders.

4. The Company is primarily engaged in the business of manufacture and sale of "Medical Devices" and, hence, there is no reportable segments as per Accounting Standard-17 issued by ICAI.

5. The consolidated Financial Statement has been prepared in accordance with AS- 21 "Consolidated Financial Statements" and AS-23 "Accounting for investment in Associates in Consolidated Financial Statements".

6. There was no pending complaint either at the beginning or end of the quarter ended 31st March, 2012.

7. Previous period/year figures have been rearranged/regrouped in conformity with revised Schedule VI.


By order of the Board

Himanshu Bald
Managing Director

Place : New Delhi
Date : 28.05.2012